Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit

Daniel F Kripke, Daniel F Kripke

Abstract

This is a review of hypnotic drug risks and benefits. Almost every month, new information appears about the risks of hypnotics (sleeping pills). The most important risks of hypnotics include excess mortality (especially overdose deaths, quiet deaths at night, and suicides), infections, cancer, depression, automobile crashes, falls, other accidents, and hypnotic-withdrawal insomnia. Short-term use of one-two prescriptions is associated with even greater risk per dose than long-term use. Hypnotics have usually been prescribed without approved indication, most often with specific contraindications, but even when indicated, there is little or no benefit. The recommended doses objectively increase sleep little if at all, daytime performance is often made worse (not better) and the lack of general health benefits is commonly misrepresented in advertising. Treatments such as the cognitive behavioral treatment of insomnia and bright light treatment of circadian rhythm disorders offer safer and more effective alternative approaches to insomnia.

Keywords: cancer; depression; hypnotics and sedatives; infection; insomnia; mortality; sleep.

Conflict of interest statement

Competing interests: Since 1979 publication of hypnotics’ epidemiology from the American Cancer Society CPSI study, the author has been a frequent critic of hypnotics risks and benefits, especially through his non-profit internet web site, http://www.DarkSideOfSleepingPills.com, that offers readers additional information and references about hypnotics. Dr. Kripke's family owns non-controlling stock in a large conglomerate that in turn invested a tiny percentage of its capital in Sanofi-Aventis and other manufacturers of hypnotics. The author has advised the USA Food and Drug Administration to take certain actions regarding hypnotics (Petition available at http://www.regulations.gov/#!docketDetail;D=FDA-2015-P-3959). Litigation to mitigate the leading hypnotic generics manufacturer and a leading California pharmacy provider has been commenced. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, other stock ownership or options, expert testimony, grants or patents received or pending or royalties. No writing assistance was utilized in the production of this manuscript.

References

    1. Rudd RA, Aleshire N, Zibbell JE, et al. : Increases in Drug and Opioid Overdose Deaths--United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82. 10.15585/mmwr.mm6450a3
    1. Ahman FB, Rossen LM, Spencer MR, et al. : Provisional drug overdose death counts.National Center for Health Statistics. Vital Statistics Rapid Release. 2018.
    1. Rockett IR, Lilly CL, Jia H, et al. : Self-injury Mortality in the United States in the Early 21st Century: A Comparison With Proximally Ranked Diseases. JAMA Psychiatry. 2016;73(10):1072–81. 10.1001/jamapsychiatry.2016.1870
    1. Ford ES, Wheaton AG, Cunningham TJ, et al. : Trends in Outpatient Visits for Insomnia, Sleep Apnea, and Prescriptions for Sleep Medications among US Adults: Findings from the National Ambulatory Medical Care Survey 1999–2010. Sleep. 2014;37(8):1283–93. 10.5665/sleep.3914
    1. Crow D: Ambien defence: the real side effects of sleeping pills. Financial Times Sect. US.2018.
    1. Jalal H, Buchanich JM, Roberts MS, et al. : Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361(6408): pii: eaau1184. 10.1126/science.aau1184
    1. Doctor JN, Nguyen A, Lev R, et al. : Opioid prescribing decreases after learning of a patient's fatal overdose. Science. 2018;361(6402):588–90. 10.1126/science.aat4595
    1. Jones JD, Mogali S, Comer SD: Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8–18. 10.1016/j.drugalcdep.2012.07.004
    1. Larochelle MR, Zhang F, Ross-Degnan D, et al. : Trends in opioid prescribing and co-prescribing of sedative hypnotics for acute and chronic musculoskeletal pain: 2001–2010. Pharmacoepidemiol Drug Saf. 2015;24(8):885–92. 10.1002/pds.3776
    1. Liang Y, Goros MW, Turner BJ: Drug Overdose: Differing Risk Models for Women and Men among Opioid Users with Non-Cancer Pain. Pain Med. 2016;17(12):2268–79. 10.1093/pm/pnw071
    1. Turner BJ, Liang Y: Drug Overdose in a Retrospective Cohort with Non-Cancer Pain Treated with Opioids, Antidepressants, and/or Sedative-Hypnotics: Interactions with Mental Health Disorders. J Gen Intern Med. 2015;30(8):1081–96. 10.1007/s11606-015-3199-4
    1. Dowell D, Arias E, Kochanek K, et al. : Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015. JAMA. 2017;318(11):1065–7. 10.1001/jama.2017.9308
    1. Kolata G, Cohen S: Drug overdoses propel rise in mortality rates of young whites. International NY Times. 2016.
    1. Case A, Deaton A: Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078–83. 10.1073/pnas.1518393112
    1. Substance Abuse and Mental Health Services Administration CfBHSaQ: The DAWN Report: Benzodiazepines in combination with opioid pain relievers or alcohol: Greater risk of more serious ED visit outcomes. Dawn. 2014;192:1–6.
    1. Curtin SC, Warner M, Hedegaard H: Increase in Suicide in the United States, 1999–2014. Hyattsville, M.D., National Center for Health Statistics. NCHS Data Brief. 2016; (241):1–8.
    1. Krueger AB: Where Have All the Workers Gone? An Inquiry into the Decline of the U.S. Labor Force Participation Rate. Brookings Papers on Economic Activity. 2017;2017:1–87.
    1. Jennum P, Baandrup L, Iversen HK, et al. : Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study. BMJ Open. 2016;6(3):e010662. 10.1136/bmjopen-2015-010662
    1. Merlo J, Hedblad B, Ogren M, et al. : Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Results of the 10-year follow-up of the prospective population study "Men born in 1914", Malmo, Sweden. Eur J Clin Pharmacol. 1996;49(4):261–5. 10.1007/BF00226325
    1. Lan TY, Zeng YF, Tang GJ, et al. : The Use of Hypnotics and Mortality--A Population-Based Retrospective Cohort Study. PLoS One. 2015;10(12):e0145271. 10.1371/journal.pone.0145271
    1. Patorno E, Glynn RJ, Levin R, et al. : Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ. 2017;358:j2941. 10.1136/bmj.j2941
    1. Kripke DF: Mortality Risk of Hypnotics: Strengths and Limits of Evidence. Drug Saf. 2016;39(2):93–107. 10.1007/s40264-015-0362-0
    1. Ioannidis JP: Exposure-wide epidemiology: revisiting Bradford Hill. Stat Med. 2016;35(11):1749–62. 10.1002/sim.6825
    1. Palmaro A, Dupouy J, Lapeyre-Mestre M: Benzodiazepines and risk of death: Results from two large cohort studies in France and UK. Eur Neuropsychopharmacol. 2015;25(10):1566–77. 10.1016/j.euroneuro.2015.07.006
    1. Chung WS, Lai CY, Lin CL, et al. : Adverse Respiratory Events Associated With Hypnotics Use in Patients of Chronic Obstructive Pulmonary Disease: A Population-Based Case-Control Study. Medicine (Baltimore). 2015;94(27):e1110. 10.1097/MD.0000000000001110
    1. Kripke DF, Langer RD, Kline LE: Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1):e000850. 10.1136/bmjopen-2012-000850
    1. Weich S, Pearce HL, Croft P, et al. : Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996. 10.1136/bmj.g1996
    1. Neutel CI, Johansen HL: Association between hypnotics use and increased mortality: causation or confounding? Eur J Clin Pharmacol. 2015;71(5):637–42. 10.1007/s00228-015-1841-z
    1. Kripke DF, Garfinkel L, Wingard DL, et al. : Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry. 2002;59(2):131–6. 10.1001/archpsyc.59.2.131
    1. Geulayov G, Ferrey A, Casey D, et al. : Relative toxicity of benzodiazepines and hypnotics commonly used for self-poisoning: An epidemiological study of fatal toxicity and case fatality. J Psychopharmacol. 2018;32(6):654–662. 10.1177/0269881118754734
    1. Chen HC, Su TP, Chou P: A nine-year follow-up study of sleep patterns and mortality in community-dwelling older adults in Taiwan. Sleep. 2013;36(8):1187–98. 10.5665/sleep.2884
    1. Mallon L, Broman JE, Hetta J: Is usage of hypnotics associated with mortality? Sleep Med. 2009;10(3):279–86. 10.1016/j.sleep.2008.12.004
    1. Belleville G: Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey. Can J Psychiatry. 2010;55(9):558–67. 10.1177/070674371005500904
    1. Kripke DF: Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007;7:42. 10.1186/1471-244X-7-42
    1. Kripke DF: Hypnotics cause insomnia: evidence from clinical trials. Sleep Med. 2014;15(9):1168–9. 10.1016/j.sleep.2014.08.001
    1. Cooper JR: Sedative-Hypnotic Drugs: Risks and Benefits. Rockville, MD: U.S. Department of HEW, National Inst. on Drug Abuse;1977.
    1. Kripke DF, Garfinkel L: Excess nocturnal deaths related to sleeping pill and tranquilliser use. Lancet. 1984;1(8368):99. 10.1016/S0140-6736(84)90022-9
    1. Leary S, Members of Panel : AVMA Guidelines for the Euthanasia of Animals: 2013.Edition 2013.0.1. Schaumburg, IL: American Veterinary Medical Association;2013.
    1. Wikibooks contributors: Pentobarbital.Accessed 8-26-2015. Wikibooks, The Free Textbook Project. Wikibooks.
    1. Farkas RH, Katz R, Illoh K, et al. : Application Number 204569Orig1s000: Medical Review(s). Accessed 6-25-2013.
    1. Okamoto M, Rao SN, Aaronson LM, et al. : Ethanol drug interaction with chlordiazepoxide and pentobarbital. Alcohol Clin Exp Res. 1985;9(6):516–21. 10.1111/j.1530-0277.1985.tb05595.x
    1. Lalley PM: Opioidergic and dopaminergic modulation of respiration. Respir Physiol Neurobiol. 2008;164(1–2):160–7. 10.1016/j.resp.2008.02.004
    1. Joya FL, Kripke DF, Loving RT, et al. : Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009;5(4):377–83.
    1. Farkas R, Center for Drug Evaluation and Research : Approval Package for: Application Number: 019908Orig1s032s034 021774Orig1s013s015. Accessed 2013. Silver Spring, MD, FDA.2013.
    1. Obiora E, Hubbard R, Sanders RD, et al. : The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(2):163–70. 10.1136/thoraxjnl-2012-202374
    1. Maeda T, Babazono A, Nishi T, et al. : Quantification of adverse effects of regular use of triazolam on clinical outcomes for older people with insomnia: a retrospective cohort study. Int J Geriatr Psychiatry. 2016;31(2):186–94. 10.1002/gps.4310
    1. Iqbal U, Syed-Abdul S, Nguyen PA, et al. : The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(6):591–2. 10.1136/thoraxjnl-2013-203211
    1. Huang CY, Chou FH, Huang YS, et al. : The association between zolpidem and infection in patients with sleep disturbance. J Psychiatr Res. 2014;54(7):116–20. 10.1016/j.jpsychires.2014.03.017
    1. Liao KF, Lin CL, Lai SW, et al. : Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. Medicine (Baltimore). 2015;94(32):e1302. 10.1097/MD.0000000000001302
    1. Lai SW, Lin CL, Liao KF: Increased relative risk of acute pancreatitis in zolpidem users. Psychopharmacology (Berl). 2015;232(12):2043–8. 10.1007/s00213-014-3833-6
    1. Hsu FG, Sheu MJ, Lin CL, et al. : Use of Zolpidem and Risk of Acute Pyelonephritis in Women: A Population-Based Case-Control Study in Taiwan. J Clin Pharmacol. 2017;57(3):376–81. 10.1002/jcph.815
    1. Lai SW, Lai HC, Lin CL, et al. : Zopiclone use associated with increased risk of acute pancreatitis: a case-control study in Taiwan. Int J Clin Pract. 2015;69(11):1275–80. 10.1111/ijcp.12689
    1. Nakafero G, Sanders RD, Nguyen-Van-Tam JS, et al. : Association between benzodiazepine use and exacerbations and mortality in patients with asthma: a matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2015;24(8):793–802. 10.1002/pds.3799
    1. Pavon JM, Zhao Y, McConnell E, et al. : Identifying risk of readmission in hospitalized elderly adults through inpatient medication exposure. J Am Geriatr Soc. 2014;62(6):1116–21. 10.1111/jgs.12829
    1. Sanders RD, Godlee A, Fujimori T, et al. : Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice. Crit Care Med. 2013;41(7):1627–36. 10.1097/CCM.0b013e31827c0c8d
    1. Huemer HP, Lassnig C, Nowotny N, et al. : Diazepam leads to enhanced severity of orthopoxvirus infection and immune suppression. Vaccine. 2010;28(38):6152–8. 10.1016/j.vaccine.2010.07.032
    1. Massoco C, Palermo-Neto J: Effects of midazolam on equine innate immune response: a flow cytometric study. Vet Immunol Immunopathol. 2003;95(1–2):11–9. 10.1016/S0165-2427(03)00097-7
    1. Torres SR, Fröde TS, Nardi GM, et al. : Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur J Pharmacol. 2000;408(2):199–211. 10.1016/S0014-2999(00)00760-3
    1. Kripke DF: Possibility that certain hypnotics might cause cancer in skin. J Sleep Res. 2008;17(3):245–50. 10.1111/j.1365-2869.2008.00685.x
    1. Roth T, Zammit GK, Scharf MB, et al. : Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep. Sleep. 2007;30(12):1731–8.
    1. Scharf MB, Black J, Hull S, et al. : Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep. 2007;30(6):743–52. 10.1093/sleep/30.6.743
    1. Weissinger J: NDA 19-908 Ambien Pharmacology Memos & Exclusivity Summary.1991.
    1. Andreason PJ, Brugge K, Katz R, Center for Drug Evaluation and Research : Approval Package for: Application Number 21-476: Medical Review(s).2004.
    1. Amerio A, Gálvez JF, Odone A, et al. : Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration-required preclinical in vivo studies. Aust N Z J Psychiatry. 2015;49(8):686–96. 10.1177/0004867415582231
    1. Roca R, McNeil DE, Center for Drug Evaluation and Research: Application Number 21-782: Medical Review(s).2005;1–315.
    1. Fitzgerald GG, Center for Drug Evaluation and Research: Application Number 020859: Pharmacology Review(s). FDA,1998.
    1. Wikipedia contributors: Clastogen.Wikipedia, Accessed 6-20-2014.
    1. Wasserman A, Mellon RD, Center for Drug Evaluation and Research: Application number 21-774: Pharmacology Reviews(s). FDA,2005.
    1. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. 10.1016/j.cell.2010.01.025
    1. Mallon L, Broman JE, Hetta J: Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Int Med. 2002;251(3):207–16. 10.1046/j.1365-2796.2002.00941.x
    1. Kripke DF, Klauber MR, Wingard DL, et al. : Mortality hazard associated with prescription hypnotics. Biol Psychiatry. 1998;43(9):687–93. 10.1016/S0006-3223(97)00292-8
    1. Hartz A, Ross JJ: Cohort study of the association of hypnotic use with mortality in postmenopausal women. BMJ Open. 2012;2(5): pii:e001413. 10.1136/bmjopen-2012-001413
    1. Kao CH, Sun LM, Liang JA, et al. : Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc. 2012;87(5):430–6. 10.1016/j.mayocp.2012.02.012
    1. Wen CP, Levy DT, Cheng TY, et al. : Smoking behaviour in Taiwan, 2001. Tob Control. 2005;14 Suppl 1:i51–i55. 10.1136/tc.2004.008011
    1. Chu NF: Prevalence of obesity in Taiwan. Obes Rev. 2005;6(4):271–4. 10.1111/j.1467-789X.2005.00175.x
    1. Lai SW, Lin CL, Liao KF: Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan. Front Pharmacol. 2017;8:767. 10.3389/fphar.2017.00767
    1. Kao CH, Sun LM, Su KP, et al. : Benzodiazepine use possibly increases cancer risk: a population-based retrospective cohort study in Taiwan. J Clin Psychiatry. 2012;73(4):e555–e560. 10.4088/JCP.11m07333
    1. Iqbal U, Jian WS, Huang CW, et al. : Do all hypnotic and sedatives have risk for cancer? Sleep Med. 2015;20:170. 10.1016/j.sleep.2015.07.010
    1. Jiao L, Duan Z, Sangi-Haghpeykar H, et al. : Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer. 2013;108(1):213–21. 10.1038/bjc.2012.561
    1. Pottegård A, Friis S, Andersen M, et al. : Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2013;75(5):1356–64. 10.1111/bcp.12001
    1. Sivertsen B, Salo P, Pentti J, et al. : Use of sleep medications and risk of cancer: a matched case-control study. Sleep Med. 2015;16(12):1552–5. 10.1016/j.sleep.2015.05.003
    1. Kripke DF, Langer RD: Evidence for harm, comment on 'Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study'. Br J Clin Pharmacol. 2014;78(1):186–7. 10.1111/bcp.12265
    1. Gagliardi GS, Shah AP, Goldstein M, et al. : Effect of zolpidem on the sleep arousal response to nocturnal esophageal acid exposure. Clin Gastroenterol Hepatol. 2009;7(9):948–52. 10.1016/j.cgh.2009.04.026
    1. Kim DH, Kim HB, Kim YH, et al. : Use of Hypnotics and Risk of Cancer: A Meta-Analysis of Observational Studies. Korean J Fam Med. 2018;39(4):211–8. 10.4082/kjfm.17.0025
    1. Friedman GD, Udaltsova N, Chan J, et al. : Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009;20(10):1821–35. 10.1007/s10552-009-9375-2
    1. Friedman GD, Jiang SF, Udaltsova N, et al. : Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer. 2009;125(9):2173–8. 10.1002/ijc.24545
    1. Zhang T, Yang X, Zhou J, et al. : Benzodiazepine drug use and cancer risk: a dose-response meta analysis of prospective cohort studies. Oncotarget. 2017;8(60):102381–91. 10.18632/oncotarget.22057
    1. Youssef NA, Rich CL: Does acute treatment with sedatives/hypnotics for anxiety in depressed patients affect suicide risk? A literature review. Ann Clin Psychiatry. 2008;20(3):157–69. 10.1080/10401230802177698
    1. Wu JQ, Appleman ER, Salazar RD, et al. : Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis. JAMA Intern Med. 2015;175(9):1461–72. 10.1001/jamainternmed.2015.3006
    1. Luik AI, Kyle SD, Espie CA: Digital Cognitive Behavioral Therapy (dCBT) for Insomnia: a State-of-the-Science Review. Curr Sleep Med Rep. 2017;3(2):48–56. 10.1007/s40675-017-0065-4
    1. Freeman D, Sheaves B, Goodwin GM, et al. : The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis. Lancet Psychiatry. 2017;4(10):749–758. 10.1016/S2215-0366(17)30328-0
    1. Fava M, McCall WV, Krystal A, et al. : Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052–60. 10.1016/j.biopsych.2006.01.016
    1. Fava M, Asnis GM, Shrivastava RK, et al. : Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 2011;72(7):914–28. 10.4088/JCP.09m05571gry
    1. Sun Y, Lin CC, Lu CJ, et al. : Association Between Zolpidem and Suicide: A Nationwide Population-Based Case-Control Study. Mayo Clin Proc. 2016;91(3):308–15. 10.1016/j.mayocp.2015.10.022
    1. Tan TL, Bixler EO, Kales A, et al. : Early morning insomnia, daytime anxiety, and organic mental disorder associated with triazolam. J Fam Pract. 1985;20(6):592–4.
    1. Rockett IR, Caine ED: Self-injury is the eighth leading cause of death in the United States: It is time to pay attention. JAMA Psychiatry. 2015;72(11):1069–70. 10.1001/jamapsychiatry.2015.1418
    1. Levi J, Segal LM, Martin A: The Facts Hurt: A state-by-state injury prevention policy report.Washington, D.C.: Trust for America's Health;2015.
    1. Pressman MR: Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med Rev. 2011;15(5):285–92. 10.1016/j.smrv.2010.12.004
    1. Breiding MJ, Wiersema B: Variability of undetermined manner of death classification in the US. Inj Prev. 2006;12 Suppl 2:ii49–ii54. 10.1136/ip.2006.012591
    1. Carlsten A, Waern M: Are sedatives and hypnotics associated with increased suicide risk of suicide in the elderly? BMC Geriatr. 2009;9(1):20. 10.1186/1471-2318-9-20
    1. Brower KJ, McCammon RJ, Wojnar M, et al. : Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry. 2011;72(4):515–21. 10.4088/JCP.09m05484gry
    1. Gunnell D, Chang SS, Tsai MK, et al. : Sleep and suicide: an analysis of a cohort of 394,000 Taiwanese adults. Soc Psychiatry Psychiatr Epidemiol. 2013;48(9):1457–65. 10.1007/s00127-013-0675-1
    1. Gregory AM, Rijsdijk FV, Eley TC, et al. : A Longitudinal Twin and Sibling Study of Associations between Insomnia and Depression Symptoms in Young Adults. Sleep. 2016;39(11):1985–92. 10.5665/sleep.6228
    1. Darke S, Deady M, Duflou J: Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001–2010. J Forensic Sci. 2012;57(5):1259–62. 10.1111/j.1556-4029.2012.02117.x
    1. Johnson LC, Chernik DA: Sedative-hypnotics and human performance. Psychopharmacology (Berl). 1982;76(2):101–13. 10.1007/BF00435262
    1. Drover D, Lemmens H, Naidu S, et al. : Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther. 2000;22(12):1443–61. 10.1016/S0149-2918(00)83043-X
    1. Poceta JS: Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8. 10.5664/jcsm.1468
    1. Tsai JH, Yang P, Chen CC, et al. : Zolpidem-induced amnesia and somnambulism: rare occurrences? Eur Neuropsychopharmacol. 2009;19(1):74–6. 10.1016/j.euroneuro.2008.08.007
    1. Morgenthaler TI, Silber MH: Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med. 2002;3(4):323–7. 10.1016/S1389-9457(02)00007-2
    1. McCall WV, Benca RM, Rosenquist PB, et al. : Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. Am J Psychiatry. 2017;174(1):18–25. 10.1176/appi.ajp.2016.16030336
    1. Wium-Andersen MK, Orsted DD, Nordestgaard BG: Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: a mendelian randomization study. Biol Psychiatry. 2014;76(3):249–57. 10.1016/j.biopsych.2013.10.009
    1. Batty GD, Bell S, Stamatakis E, et al. : Association of Systemic Inflammation With Risk of Completed Suicide in the General Population. JAMA Psychiatry. 2016;73(9):993–5. 10.1001/jamapsychiatry.2016.1805
    1. Wium-Andersen MK, Ørsted DD, Nordestgaard BG: Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. Br J Psychiatry. 2016;208(2):138–45. 10.1192/bjp.bp.114.150870
    1. Barnes J, Mondelli V, Pariante CM: Genetic Contributions of Inflammation to Depression. Neuropsychopharmacol. 2017;42(1):81–98. 10.1038/npp.2016.169
    1. Jansen R, Penninx BW, Madar V, et al. : Gene expression in major depressive disorder. Mol Psychiatry. 2016;21(3):339–47. 10.1038/mp.2015.57
    1. Ma K, Zhang H, Baloch Z: Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. Int J Mol Sci. 2016;17(5): pii: E733. 10.3390/ijms17050733
    1. Oster G, Huse DM, Adams SF, et al. : Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health. 1990;80(12):1467–70. 10.2105/AJPH.80.12.1467
    1. Lai MM, Lin CC, Lin CC, et al. : Long-term use of zolpidem increases the risk of major injury: a population-based cohort study. Mayo Clin Proc. 2014;89(5):589–94. 10.1016/j.mayocp.2014.01.021
    1. Chung SD, Lin CC, Wang LH, et al. : Zolpidem Use and the Risk of Injury: A Population-Based Follow-Up Study. PLoS One. 2013;8(6):e67459. 10.1371/journal.pone.0067459
    1. Verster JC, Veldhuijzen DS, Patat A, et al. : Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63–71. 10.2174/157488606775252674|
    1. Verster JC, Spence DW, Shahid A, et al. : Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf. 2011;6(4):209–18. 10.2174/157488611798280933|
    1. Verster JC, Roth T: Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology (Berl). 2012;219(3):775–81. 10.1007/s00213-011-2400-7
    1. Yang YH, Lai JN, Lee CH, et al. : Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol. 2011;21(1):37–43. 10.2188/jea.JE20090195
    1. Orriols L, Philip P, Moore N, et al. : Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595–601. 10.1038/clpt.2011.3
    1. Philip P, Chaufton C, Orriols L, et al. : Complaints of Poor Sleep and Risk of Traffic Accidents: A Population-Based Case-Control Study. PLoS One. 2014;9(12):e114102. 10.1371/journal.pone.0114102
    1. Hansen RN, Boudreau DM, Ebel BE, et al. : Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash. Am J Public Health. 2015;105(8):e64–e69. 10.2105/AJPH.2015.302723
    1. Hemmelgarn B, Suissa S, Huang A, et al. : Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278(1):27–31. 10.1001/jama.1997.03550010041037
    1. Gustavsen I, Bramness JG, Skurtveit S, et al. : Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. 2008;9(8):818–22. 10.1016/j.sleep.2007.11.011
    1. Nevriana A, Möller J, Laflamme L, et al. : New, Occasional, and Frequent Use of Zolpidem or Zopiclone (Alone and in Combination) and the Risk of Injurious Road Traffic Crashes in Older Adult Drivers: A Population-Based Case-Control and Case-Crossover Study. CNS Drugs. 2017;31(8):711–722. 10.1007/s40263-017-0445-9
    1. Hedlund J, Ahlner J, Kristiansson M, et al. : A population-based study on toxicological findings in Swedish homicide victims and offenders from 2007 to 2009. Forensic Sci Int. 2014;244:25–9. 10.1016/j.forsciint.2014.07.015
    1. Tinetti ME, Speechley M, Ginter SF: Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701–7. 10.1056/NEJM198812293192604
    1. Wang PS, Bohn RL, Glynn RJ, et al. : Hazardous benzodiazepine regimens in the elderly: Effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158(6):892–8. 10.1176/appi.ajp.158.6.892
    1. Wang PS, Bohn RL, Glynn RJ, et al. : Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49(12):1685–90. 10.1111/j.1532-5415.2001.49280.x
    1. Cumming RG, Le Couteur DG: Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17(11):825–37. 10.2165/00023210-200317110-00004
    1. Kang DY, Park S, Rhee CW, et al. : Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health. 2012;45(4):219–26. 10.3961/jpmph.2012.45.4.219
    1. Berry SD, Lee Y, Cai S, et al. : Nonbenzodiazepine Sleep Medication Use and Hip Fractures in Nursing Home Residents. JAMA Intern Med. 2013;173(9):754–61. 10.1001/jamainternmed.2013.3795
    1. Kolla BP, Lovely JK, Mansukhani MP, et al. : Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med. 2013;8(1):1–6. 10.1002/jhm.1985
    1. Diem SJ, Ewing SK, Stone KL, et al. : Use of non-benzodiazepine sedative hypnotics and risk of falls in older men. J Gerontol Geriatr Res. 2014;3(3):158. 10.4172/2167-7182.1000158
    1. Park SM, Ryu J, Lee DR, et al. : Zolpidem use and risk of fractures: a systematic review and meta-analysis. Osteoporos press,2016;27(10):2935–44. 10.1007/s00198-016-3605-8
    1. Frisher M, Gibbons N, Bashford J, et al. : Melatonin, hypnotics and their association with fracture: a matched cohort study. Age Ageing. 2016;45(6):801–6. 10.1093/ageing/afw123
    1. Tom SE, Wickwire EM, Park Y, et al. : Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury. Sleep. 2016;39(5):1009–14. 10.5665/sleep.5742
    1. Donnelly K, Bracchi R, Hewitt J, et al. : Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS One. 2017;12(4):e0174730. 10.1371/journal.pone.0174730
    1. Avidan AY, Fries BE, James ML, et al. : Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53(6):955–62. 10.1111/j.1532-5415.2005.53304.x
    1. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel: American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227–46. 10.1111/jgs.13702
    1. Kripke DF, Ancoli-Israel S, Klauber MR, et al. : Prevalence of sleep-disordered breathing in ages 40-64 years: A population-based survey. Sleep. 1997;20(1):65–76. 10.1093/sleep/20.1.65
    1. Ancoli-Israel S, Kripke DF, Klauber MR, et al. : Sleep-disordered breathing in community-dwelling elderly. Sleep. 1991;14(6):486–95. 10.1093/sleep/14.6.486
    1. Jann M, Kennedy WK, Lopez G: Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract. 2014;27(1):5–16. 10.1177/0897190013515001
    1. Webster LR, Choi Y, Desai H, et al. : Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4):425–32. 10.1111/j.1526-4637.2007.00343.x
    1. Mogri M, Desai H, Webster L, et al. : Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath. 2009;13(1):49–57. 10.1007/s11325-008-0208-4
    1. Park TW, Saitz R, Ganoczy D, et al. : Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. 10.1136/bmj.h2698
    1. Weisberg DF, Gordon KS, Barry DT, et al. : Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr. 2015;69(2):223–33. 10.1097/QAI.0000000000000591
    1. Dwyer LL, Lau DT, Shega JW: Medications That Older Adults in Hospice Care in the United States Take, 2007. J Am Geriatr Soc. 2015;63(11):2282–9. 10.1111/jgs.13795
    1. Moore TJ: ISMP Quarter Watch: Monitoring FDA MedWatch Reports. Accessed 5-06-2015. Philadelphia, PA, ISMP. Quarter Watch.
    1. Hampton LM, Daubresse M, Chang HY, et al. : Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. JAMA Psychiatry. 2014;71(9):1006–14. 10.1001/jamapsychiatry.2014.436
    1. Dowell D, Haegerich TM, Chou R: CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016;315(15):1624–45. 10.1001/jama.2016.1464
    1. Harward JL, Clinard VB, Jiroutek MR, et al. : Impact of a US Food and Drug Administration Drug Safety Communication on Zolpidem Dosing: An Observational Retrospective Cohort. Prim Care Companion CNS Disord. 2015;17(2). 10.4088/PCC.14m01728
    1. Bertisch SM, Herzig SJ, Winkelman JW, et al. : National use of prescription medications for insomnia: NHANES 1999–2010. Sleep. 2014;37(2):343–9. 10.5665/sleep.3410
    1. Moore TJ, Mattison DR: Assessment of Patterns of Potentially Unsafe Use of Zolpidem. JAMA Intern Med. 2018;178(9):1275–1277. 10.1001/jamainternmed.2018.3031
    1. Lipari RN, Williams M, Van Horn SL: Why Do Adults Misuse Prescription Drugs? Rockville, MD Center for Behavioral Health Statistics and Quality, SAMHSA. The CBHSQ Report.2017. |
    1. Ponté C, Lepelley M, Boucherie Q, et al. : Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018;187:88–94. 10.1016/j.drugalcdep.2018.01.036
    1. Riemann D, Baglioni C, Bassetti C, et al. : European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700. 10.1111/jsr.12594
    1. Institute of Medicine (US) Committee on Halcion: An Assessment of Data Adequacy and Confidence: Halcion: An Independent Assessment of Safety and Efficacy Data.Washington, D.C.: National Academy Press;1997. 10.17226/5940
    1. Harnod T, Wang YC, Kao CH: Association Between Benzodiazepine Use and Epilepsy Occurrence: A Nationwide Population-Based Case-Control Study. Medicine (Baltimore). 2015;94(37):e1571. 10.1097/MD.0000000000001571
    1. Hammond EC: Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health Nations Health. 1964;54(1):11–23. 10.2105/AJPH.54.1.11
    1. Kripke DF, Langer RD, Elliott JA, et al. : Mortality related to actigraphic long and short sleep. Sleep Med. 2011;12(1):28–33. 10.1016/j.sleep.2010.04.016
    1. Kripke DF, Simons RN, Garfinkel L, et al. : Short and long sleep and sleeping pills. Is increased mortality associated? Arch Gen Psychiatry. 1979;36(1):103–16. 10.1001/archpsyc.1979.01780010109014
    1. da Silva AA, de Mello RG, Schaan CW, et al. : Sleep duration and mortality in the elderly: a systematic review with meta-analysis. BMJ Open. 2016;6(2):e008119. 10.1136/bmjopen-2015-008119
    1. Shen X, Wu Y, Zhang D: Nighttime sleep duration, 24-hour sleep duration and risk of all-cause mortality among adults: a meta-analysis of prospective cohort studies. Sci Rep. 2016;6:21480. 10.1038/srep21480
    1. Kabat GC, Xue X, Kamensky V, et al. : The association of sleep duration and quality with all-cause and cause-specific mortality in the Women's Health Initiative. Sleep Med. 2018;50(10):48–54. 10.1016/j.sleep.2018.05.015
    1. Choi JW, Lee J, Jung SJ, et al. : Use of Sedative-Hypnotics and Mortality: A Population-Based Retrospective Cohort Study. J Clin Sleep Med. 2018;14(10):1669–77. 10.5664/jcsm.7370
    1. Lawman HG, Fryar D, Gu Q, et al. : The role of prescription medications in the association of self-reported sleep duration and obesity in U.S. adults, 2007–2012. Obesity (Silver Spring). 2016;24(10):2210–6. 10.1002/oby.21600
    1. Buscemi N, Vandermeer B, Friesen C, et al. : The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335–50. 10.1007/s11606-007-0251-z
    1. Farkas RH, Unger EF, Temple R: Zolpidem and driving impairment--identifying persons at risk. N Engl J Med. 2013;369(8):689–91. 10.1056/NEJMp1307972
    1. Rosenberg R, Caron J, Roth T, et al. : An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med. 2005;6(1):15–22. 10.1016/j.sleep.2004.09.001
    1. Scharf M, Erman M, Rosenberg R, et al. : A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28(6):720–7. 10.1093/sleep/28.6.720
    1. Buxton OM, Pavlova MK, O'Connor SP, et al. : Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients. Nat Sci Sleep. 2017;9:187–98. 10.2147/NSS.S130505
    1. Brasure M, MacDonald R, Fuchs E, et al. : Management of Insomnia Disorder [Internet]. AHRQ Publication No. 15(16)-EHC027-EF, Accessed 12-30-2015. Rockville, MD, USA, Agency for Healthcare Research and Quality. Comparative Effectiveness Review.1–288.
    1. Giles J: Drug trials: stacking the deck. Nature. 2006;440(7082):270–2. 10.1038/440270a
    1. Mattila T, Stoyanova V, Elferink A, et al. : Insomnia medication: do published studies reflect the complete picture of efficacy and safety? Eur Neuropsychopharmacol. 2011;21(7):500–7. 10.1016/j.euroneuro.2010.10.005
    1. Chiu HY, Lin EY, Wei L, et al. : Hypnotics use but not insomnia increased the risk of dementia in traumatic brain injury patients. Eur Neuropsychopharmacol. 2015;25(12):2271–7. 10.1016/j.euroneuro.2015.09.011
    1. Roehrs T, Verster JC, Koshorek G, et al. : How representative are insomnia clinical trials? Sleep Med. 2018;51:118–23. 10.1016/j.sleep.2018.06.003
    1. Wilt TJ, MacDonald R, Brasure M, et al. : Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):103–12. 10.7326/M15-1781
    1. Beaulieu-Bonneau S, Ivers H, Guay B, et al. : Long-Term Maintenance of Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia Delivered Alone or Combined With Zolpidem. Sleep. 2017;40(3): zsx002. 10.1093/sleep/zsx002
    1. Sateia MJ, Buysse D, Krystal AD, et al. : Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–49. 10.5664/jcsm.6470
    1. Sateia MJ: Increasing public awareness. J Clin Sleep Med. 2005;1(2):117–8.
    1. Boyle J, Groeger JA, Paska W, et al. : A method to assess the dissipation of the [corrected] residual effects of [corrected] hypnotics: eszopiclone versus zopiclone. J Clin Psychopharmacol. 2012;32(5):704–9. 10.1097/JCP.0b013e3182664eec
    1. Stranks EK, Crowe SF: The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol. 2014;36(7):691–700. 10.1080/13803395.2014.928268
    1. Kripke DF: I petitioned the FDA to restrict hypnotics: here is why. Sleep press,2016;23:119–120. 10.1016/j.sleep.2015.12.011
    1. Mellinger GD, Balter MB, Uhlenhuth EH: Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42(3):225–32. 10.1001/archpsyc.1985.01790260019002
    1. Bjorvatn B, Meland E, Flo E, et al. : High prevalence of insomnia and hypnotic use in patients visiting their general practitioner. Fam Pract. 2017;34(1):20–4. 10.1093/fampra/cmw107
    1. Maust DT, Gerlach LB, Gibson A, et al. : Trends in Central Nervous System-Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States. JAMA Intern press,2017;177(4):583–585. 10.1001/jamainternmed.2016.9225
    1. Zammit GK, McNabb LJ, Caron J, et al. : Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979–91. 10.1185/174234304X15174
    1. Schutte-Rodin S, Broch L, Buysse D, et al. : Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.
    1. Carter BD, Abnet CC, Feskanich D, et al. : Smoking and mortality--beyond established causes. N Engl J Med. 2015;372(7):631–40. 10.1056/NEJMsa1407211
    1. Tannenbaum C, Diaby V, Singh D, et al. : Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs Aging. 2015;32(4):305–14. 10.1007/s40266-015-0251-3
    1. Kripke DF: When our body clocks run late: does it make us depressed? Ann Transl press.2016;49(9):178. 10.21037/atm.2016.04.20
    1. van Maanen A, Meijer AM, van der Heijden KB, et al. : The effects of light therapy on sleep problems: A systematic review and meta-analysis. Sleep Med Rev. 2016;29:52–62. 10.1016/j.smrv.2015.08.009

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner